{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:51:10Z","timestamp":1791175870705,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-026-04671-0","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:46:40Z","timestamp":1783684000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Site-specific predictors of bone mineral density response to zoledronic acid in postmenopausal osteoporosis: differential roles of bone turnover markers and body mass index across skeletal sites"],"prefix":"10.1186","volume":"26","author":[{"given":"Chunyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingda","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"1","key":"4671_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3\u201344.","journal-title":"Osteoporos Int"},{"issue":"3","key":"4671_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3803\/EnM.2021.301","volume":"36","author":"JP Brown","year":"2021","unstructured":"Brown JP. Long-term treatment of postmenopausal osteoporosis. Endocrinol Metab (Seoul). 2021;36(3):544\u201352.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"4671_CR3","doi-asserted-by":"publisher","first-page":"p5325813","DOI":"10.1155\/2021\/5325813","volume":"2021","author":"AB Roomi","year":"2021","unstructured":"Roomi AB, Nori W, Al-Badry SH. The Value of serum adiponectin in osteoporotic women: does weight have an effect? J Obes. 2021;2021:p5325813.","journal-title":"J Obes"},{"issue":"1","key":"4671_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s13018-023-04051-6","volume":"18","author":"G Long","year":"2023","unstructured":"Long G, et al. Predictors of osteoporotic fracture in postmenopausal women: a meta-analysis. J Orthop Surg Res. 2023;18(1):574.","journal-title":"J Orthop Surg Res"},{"key":"4671_CR5","doi-asserted-by":"publisher","first-page":"p1437061","DOI":"10.1155\/2022\/1437061","volume":"2022","author":"AB Roomi","year":"2022","unstructured":"Roomi AB, et al. Evaluation of bone mineral density, serum osteocalcin, and osteopontin levels in postmenopausal women with type 2 diabetes mellitus, with\/without osteoporosis. J Osteoporos. 2022;2022:p1437061.","journal-title":"J Osteoporos"},{"issue":"4","key":"4671_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00268-019-05237-y","volume":"44","author":"SM Tarrant","year":"2020","unstructured":"Tarrant SM, Balogh ZJ. The global burden of surgical management of osteoporotic fractures. World J Surg. 2020;44(4):1009\u201319.","journal-title":"World J Surg"},{"issue":"13","key":"4671_CR7","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMc1900923","volume":"380","author":"A Chattopadhyay","year":"2019","unstructured":"Chattopadhyay A, Jain S. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2019;380(13):1287\u20138.","journal-title":"N Engl J Med"},{"issue":"17","key":"4671_CR8","first-page":"8253","volume":"27","author":"WY Wang","year":"2023","unstructured":"Wang WY, et al. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2023;27(17):8253\u201368.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"4671_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/cpt.2645","volume":"112","author":"YH Hsu","year":"2022","unstructured":"Hsu YH, et al. Reduced all-cause mortality with bisphosphonates among post-fracture osteoporosis patients: a nationwide study and systematic review. Clin Pharmacol Ther. 2022;112(3):711\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"4671_CR10","first-page":"1061","volume":"39","author":"W Fan","year":"2024","unstructured":"Fan W, et al. Zoledronic acid for hip fracture during initial hospitalization. J Bone Min Res. 2024;39(8):1061\u201370.","journal-title":"J Bone Min Res"},{"key":"4671_CR11","doi-asserted-by":"publisher","first-page":"152304","DOI":"10.1016\/j.semarthrit.2023.152304","volume":"64","author":"S Liu","year":"2024","unstructured":"Liu S, et al. Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review. Semin Arthritis Rheum. 2024;64:152304.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"4671_CR12","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595\u2013622.","journal-title":"J Clin Endocrinol Metab"},{"key":"4671_CR13","first-page":"859","volume":"14","author":"H Lin","year":"2021","unstructured":"Lin H, et al. IDUA gene variants and response to zoledronic acid treatment in Chinese women with postmenopausal osteoporosis. Pharmgenomics Pers Med. 2021;14:859\u201366.","journal-title":"Pharmgenomics Pers Med"},{"issue":"4","key":"4671_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00198-025-07448-7","volume":"36","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, et al. Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients. Osteoporos Int. 2025;36(4):707\u201314.","journal-title":"Osteoporos Int"},{"issue":"8","key":"4671_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, et al. International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011;49(8):1271\u20134.","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"4671_CR16","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","volume":"28","author":"P Szulc","year":"2017","unstructured":"Szulc P, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017;28(9):2541\u201356.","journal-title":"Osteoporos Int"},{"issue":"5","key":"4671_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/jbmr.5650080507","volume":"8","author":"DT Felson","year":"1993","unstructured":"Felson DT, et al. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Min Res. 1993;8(5):567\u201373.","journal-title":"J Bone Min Res"},{"issue":"4","key":"4671_CR18","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver CM, et al. The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int. 2016;27(4):1281\u2013386.","journal-title":"Osteoporos Int"},{"key":"4671_CR19","doi-asserted-by":"crossref","unstructured":"Wang WJ et al. Genetic polymorphisms of nuclear factor-\u03baB family affect the bone mineral density response to zoledronic acid therapy in postmenopausal Chinese women. Genes (Basel). 2022;13(8):1343.","DOI":"10.3390\/genes13081343"},{"issue":"2","key":"4671_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.3284","volume":"33","author":"SL Watson","year":"2018","unstructured":"Watson SL, et al. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Min Res. 2018;33(2):211\u201320.","journal-title":"J Bone Min Res"},{"issue":"9","key":"4671_CR21","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/jbmr.2847","volume":"31","author":"KJ Bell","year":"2016","unstructured":"Bell KJ, et al. Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data. J Bone Min Res. 2016;31(9):1767\u201373.","journal-title":"J Bone Min Res"},{"issue":"10","key":"4671_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, et al. Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Min Res. 2024;39(10):1393\u2013405.","journal-title":"J Bone Min Res"},{"key":"4671_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40842-018-0062-7","volume":"4","author":"P Choksi","year":"2018","unstructured":"Choksi P, Jepsen KJ, Clines GA. The challenges of diagnosing osteoporosis and the limitations of currently available tools. Clin Diabetes Endocrinol. 2018;4:12.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"10","key":"4671_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","volume":"64","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, et al. Denosumab in treatment-na\u00efve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metabolism. 2015;64(10):1291\u20137.","journal-title":"Metabolism"},{"issue":"4","key":"4671_CR25","doi-asserted-by":"publisher","first-page":"e1344","DOI":"10.1210\/clinem\/dgaa082","volume":"105","author":"M Nethander","year":"2020","unstructured":"Nethander M, et al. BMD-related genetic risk scores predict site-specific fractures as well as trabecular and cortical bone microstructure. J Clin Endocrinol Metab. 2020;105(4):e1344\u201357.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4671_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/ggi.12785","volume":"17","author":"Z Shou","year":"2017","unstructured":"Shou Z, et al. Reference intervals of \u03b2-C-terminal telopeptide of type I collagen, procollagen type I N-terminal propeptide and osteocalcin for very elderly Chinese men. Geriatr Gerontol Int. 2017;17(5):773\u20138.","journal-title":"Geriatr Gerontol Int"},{"issue":"5","key":"4671_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","volume":"50","author":"R Eastell","year":"2012","unstructured":"Eastell R, et al. Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Bone. 2012;50(5):1141\u20137.","journal-title":"Bone"},{"issue":"13","key":"4671_CR28","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3346\/jkms.2022.37.e68","volume":"37","author":"T Kang","year":"2022","unstructured":"Kang T, et al. Comparison of denosumab and zoledronic acid in postmenopausal women with osteoporosis: bone mineral density (BMD) and trabecular bone score (TBS). J Korean Med Sci. 2022;37(13):e68.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"4671_CR29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.archger.2015.08.010","volume":"61","author":"P Bian","year":"2015","unstructured":"Bian P, et al. Factors associated with low femoral neck bone mineral density in very elderly Chinese males. Arch Gerontol Geriatr. 2015;61(3):484\u20138.","journal-title":"Arch Gerontol Geriatr"},{"issue":"1","key":"4671_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12902-023-01389-0","volume":"23","author":"X Liu","year":"2023","unstructured":"Liu X, An J. Dietary iron intake and its impact on osteopenia\/osteoporosis. BMC Endocr Disord. 2023;23(1):154.","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"4671_CR31","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00198-021-05923-5","volume":"32","author":"KW Lyles","year":"2021","unstructured":"Lyles KW, et al. Zoledronic acid reduces the rate of clinical fractures after surgical repair of a hip fracture regardless of the Pretreatment bone mineral density. Osteoporos Int. 2021;32(6):1217\u20139.","journal-title":"Osteoporos Int"},{"key":"4671_CR32","doi-asserted-by":"crossref","unstructured":"Hsu AHS et al. Zoledronic acid ameliorates the bone turnover activity and periprosthetic bone preservation in cementless total hip arthroplasty. Pharmaceuticals (Basel). 2022;15(4):420.","DOI":"10.3390\/ph15040420"},{"issue":"1","key":"4671_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S8756-3282(03)00168-6","volume":"33","author":"P Ravn","year":"2003","unstructured":"Ravn P, et al. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone. 2003;33(1):150\u20138.","journal-title":"Bone"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04671-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04671-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04671-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:58:45Z","timestamp":1791172725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04671-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4671"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04671-0","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the ethical committee of Zhejiang Provincial People\u2019s Hospital (Affiliate People\u2019s Hospital, Hangzhou Medical College) (No. 2025\u2009\u2212\u2009194). Written informed consent was obtained from the patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"497"}}